Filing Flows › 10x Genomics (TXG) › Q2 2025
10x Genomics (TXG) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 8, 2025
10x Genomics (TXG) reported revenue of $173M for the second quarter 2025 (Q2 2025), +13% from a year earlier and +12% from the quarter before. Operating margin was 17.4%, net earnings $34.5M (20.0% of revenue).
10x Genomics, Q2 2025: revenue $173M (+13% year over year), operating margin 17.4%, net earnings $34.5M, operating cash flow $17.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $173M | +12% | +13% |
| Gross profit | $125M | +19% | +20% |
| Operating profit | $30.1M | — | — |
| Net earnings | $34.5M | — | — |
| Operating cash flow | $17.7M | -48% | +136% |
| Free cash flow | $16.1M | -50% | +249% |
What changed
Revenue was $172.9M in Q2 2025, up 13% year over year and up 12% from the previous quarter. Chromium was the largest line at 50% of revenue. License and royalty revenue added $27.6M year over year (up 24243%), 140% of the total change. Spatial declined 42%.
Gross margin was 72.3%, up 4.3 points from a year earlier. Operating profit was $30.1M, a 17.4% margin (up 44.7 points year over year). Operating expenses fell 35% while revenue rose 13%. Net earnings were $34.5M. The effective tax rate was 6.6%.
Operating cash flow was $17.7M (up 136% year over year), 51% of net earnings. Non-cash charges added back $7.8M of depreciation and amortization and $27.6M of share-based compensation. Working capital and other items used $52.2M. Capital expenditures of $1.6M left free cash flow of $16.1M.
Questions
What was 10x Genomics' revenue in the second quarter 2025?
10x Genomics (TXG) reported revenue of $173M for the second quarter 2025 (Q2 2025), +13% from a year earlier and +12% from the quarter before.
Was 10x Genomics profitable in the second quarter 2025?
Operating profit was $30.1M (17.4% of revenue) and net earnings $34.5M.
Source: 10x Genomics 10-Q on SEC EDGAR.